Lethal autoimmune hemolytic anemia in CD47-deficient nonobese diabetic (NOD) mice

被引:94
作者
Oldenborg, PA [1 ]
Gresham, HD
Chen, YM
Izui, S
Lindberg, FP
机构
[1] Umea Univ, Dept Integrat Med Biol, Sect Histol & Cell Biol, SE-90187 Umea, Sweden
[2] Washington Univ, Sch Med, Dept Med, Div Infect Dis, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Dept Mol Microbiol & Pathogenesis, St Louis, MO 63110 USA
[4] Albuquerque VA Med Ctr, Res Serv, Albuquerque, NM USA
[5] Univ New Mexico, Dept Mol Genet, Albuquerque, NM 87131 USA
[6] Univ New Mexico, Dept Microbiol, Albuquerque, NM 87131 USA
[7] Univ Geneva, Dept Pathol, CH-1211 Geneva, Switzerland
关键词
D O I
10.1182/blood.V99.10.3500
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The glycoprotein CD47 (integrin-associated protein, IAP) is present on the surface of virtually all cells, including red blood cells (RBCs). CD47 acts like a marker of self by ligating the macrophage inhibitory receptor signal regulatory protein a (SIRPalpha). In this manner mild reactivity of wild-type RBCs with macrophage phagocytic receptors Is tolerated, whereas otherwise identical CD47-deficient RBCs are rapidly eliminated. We show here that virtually all CD47-deficient nonobese diabetic (NOD) mice spontaneously develop severe lethal autoimmune hemolytic anemia (AIHA) at 180 to 280 days of age, whereas none of the control CD47(+) NOD mice develop lethal AIHA at least during the first year of life. This phenotype is at least partially due to a markedly increased rate of elimination of opsonized CD47(-/-) compared to CD47(+) RBCs. Similarly, CD47(-/-)C57BL/6 mice were much more sensitive than their wild-type counterparts to experimental passive AIHA induced by anti-RBC monoclonal antibodies. Thus, CD47-SIRPalpha signaling can have a profound Influence on the severity of AIHA, making manipulation of this signaling pathway a theoretically appealing avenue in the treatment of the disease. (C) 2002 by The American Society of Hematology.
引用
收藏
页码:3500 / 3504
页数:5
相关论文
共 23 条
[1]   The NOD mouse model of type 1 diabetes: As good as it gets? [J].
Atkinson, MA ;
Leiter, EH .
NATURE MEDICINE, 1999, 5 (06) :601-604
[2]   The Rh blood group system: a review [J].
Avent, ND ;
Reid, ME .
BLOOD, 2000, 95 (02) :375-387
[3]   HEMOLYTIC-ANEMIA IN NONOBESE DIABETIC MICE [J].
BAXTER, AG ;
MANDEL, TE .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1991, 21 (09) :2051-2055
[4]   Thrombospondin acts via integrin-associated protein to activate the platelet integrin alpha(IIb)beta(3) [J].
Chung, J ;
Gao, AG ;
Frazier, WA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (23) :14740-14746
[5]   CYTOTOXIC ANTIBODIES TRIGGER INFLAMMATION THROUGH FC-RECEPTORS [J].
CLYNES, R ;
RAVETCH, JV .
IMMUNITY, 1995, 3 (01) :21-26
[6]  
CRISPENS CG, 1975, HDB LAB MOUSE
[7]  
ENGELFRIET CP, 1992, SEMIN HEMATOL, V29, P3
[8]   Thrombospondin modulates alpha(v)beta(3) function through integrin-associated protein [J].
Gao, AG ;
Lindberg, FP ;
Dimitry, JM ;
Brown, EJ ;
Frazier, WA .
JOURNAL OF CELL BIOLOGY, 1996, 135 (02) :533-544
[9]   Role of cholesterol in formation and function of a signaling complex involving αvβ3, integrin-associated protein (CD47), and heterotrimeric G proteins [J].
Green, JM ;
Zhelesnyak, A ;
Chung, J ;
Lindberg, FP ;
Sarfati, M ;
Frazier, WA ;
Brown, EJ .
JOURNAL OF CELL BIOLOGY, 1999, 146 (03) :673-682
[10]   Organ-specific disease provoked by systemic autoimmunity [J].
Kouskoff, V ;
Korganow, AS ;
Duchatelle, V ;
Degott, C ;
Benoist, C ;
Mathis, D .
CELL, 1996, 87 (05) :811-822